Found 246 clinical trials
Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
A total of 480 Chinese women aged 18-26 years old were enrolleexperimental group and the control group were randomly assigned in a ratio of 3:1. 360 Chinese women in the experimental group and 120 in the control group. All subjects enrolled in the upper arm deltoid muscle were injected with …
- 0 views
- 16 Feb, 2024
- 1 location
Primary Organoid Models and Combined Nucleic Acids Therapeutics for Anti-HPV Treatments
Human papilloma virus (HPV) is responsible of the most common sexually transmitted infection. It can cause severe cancer lesions, of the cervix, vulva, vagina, penis and oropharynx.
- 0 views
- 16 Feb, 2024
- 1 location
Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.
The objective of this trial is to study the efficacy of treatment of human papilloma virus (HPV) related oropharyngeal cancer with chemotherapy followed by Transoral Robotic Surgery (TORS) as definitive treatment.
- 0 views
- 16 Feb, 2024
- 1 location
Screening Women With Prior HPV for Anal Neoplasia (SWAN)
The goal of this single arm trial is to prospectively evaluate screening methods for anal cancer precursors in HIV uninfected women with a history of lower genital tract neoplasias and cancers.
- 0 views
- 10 Feb, 2026
Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage
Open-label, single-center phase I study to evaluate first signs of efficacy and to confirm the safety and tolerability of a decitabine safe-dose treatment in two strata of patients with HPV induced anogenital and head and neck cancers (Stratum 1: patients with high rist for disease recurrence; Stratum 2: patients with …
- 0 views
- 16 Feb, 2024
- 1 location
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
This is a Phase II treatment, non-randomized, open label clinical trial to study the efficacy of the Cetuximab when administered as single agent in recurrent/ metastatic head and neck squamous cell carcinoma after the failure or intolerance of immuno-oncology or immuno-oncology combined with chemotherapy.
- 0 views
- 05 Aug, 2020